171 related articles for article (PubMed ID: 25139103)
1. EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study.
Bilgin Doğru E; Dizdar Y; Akşit E; Ural F; Şanlı Ö; Yasasever V
Tumour Biol; 2014 Nov; 35(11):11647-53. PubMed ID: 25139103
[TBL] [Abstract][Full Text] [Related]
2. Identification of ADAM12 as a Novel Basigin Sheddase.
Albrechtsen R; Wewer Albrechtsen NJ; Gnosa S; Schwarz J; Dyrskjøt L; Kveiborg M
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013576
[TBL] [Abstract][Full Text] [Related]
3. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy.
Bi XC; Liu JM; Zheng XG; Xian ZY; Feng ZW; Lou YX; Zhong WD; Wu CL
Clin Invest Med; 2011 Dec; 34(6):E358. PubMed ID: 22129926
[TBL] [Abstract][Full Text] [Related]
4. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer.
Shimura T; Dagher A; Sachdev M; Ebi M; Yamada T; Yamada T; Joh T; Moses MA
Cancer Prev Res (Phila); 2015 Mar; 8(3):240-8. PubMed ID: 25591790
[TBL] [Abstract][Full Text] [Related]
5. EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer.
Zhu H; Zhao J; Zhu B; Collazo J; Gal J; Shi P; Liu L; Ström AL; Lu X; McCann RO; Toborek M; Kyprianou N
Prostate; 2012 Jan; 72(1):72-81. PubMed ID: 21563192
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of ADAM12 in human bladder cancer.
Fröhlich C; Albrechtsen R; Dyrskjøt L; Rudkjaer L; Ørntoft TF; Wewer UM
Clin Cancer Res; 2006 Dec; 12(24):7359-68. PubMed ID: 17189408
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma.
Chen T; Zhu J
Med Oncol; 2010 Dec; 27(4):1185-91. PubMed ID: 19921476
[TBL] [Abstract][Full Text] [Related]
8. ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.
Xu Q; Ying M; Chen G; Lin A; Xie Y; Ohara N; Zhou D
Tumour Biol; 2014 Aug; 35(8):7575-86. PubMed ID: 24793016
[TBL] [Abstract][Full Text] [Related]
9. ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer.
Shao S; Li Z; Gao W; Yu G; Liu D; Pan F
PLoS One; 2014; 9(1):e85936. PubMed ID: 24465799
[TBL] [Abstract][Full Text] [Related]
10. The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression.
Madigan MC; Kingsley EA; Cozzi PJ; Delprado WJ; Russell PJ; Li Y
Cancer Immunol Immunother; 2008 Sep; 57(9):1367-79. PubMed ID: 18273614
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of EMMPRIN is associated with lymph node metastasis and advanced stage of non-small cell lung cancer: a retrospective study.
Liu B; Wan Z; Sheng B; Lin Y; Fu T; Zeng Q; Qi C
BMC Pulm Med; 2017 Dec; 17(1):214. PubMed ID: 29282042
[TBL] [Abstract][Full Text] [Related]
12. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer.
Dalberg K; Eriksson E; Enberg U; Kjellman M; Bäckdahl M
World J Surg; 2000 Mar; 24(3):334-40. PubMed ID: 10658069
[TBL] [Abstract][Full Text] [Related]
13. Extracellular matrix metalloproteinase inducer is a negative prognostic factor of pediatric medulloblastoma.
Chu T; Chen X; Yu J; Xiao J; Fu Z
Pathol Oncol Res; 2011 Sep; 17(3):705-11. PubMed ID: 21448785
[TBL] [Abstract][Full Text] [Related]
14. EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer.
Boye K; Nesland JM; Sandstad B; Haugland Haugen M; Mælandsmo GM; Flatmark K
Br J Cancer; 2012 Aug; 107(4):667-74. PubMed ID: 22782346
[TBL] [Abstract][Full Text] [Related]
15. Highly expressed tumoral emmprin and stromal CD73 predict a poor prognosis for external auditory canal carcinoma.
Miyazaki M; Aoki M; Okado Y; Koga K; Hamasaki M; Nakagawa T; Sakata T; Nabeshima K
Cancer Sci; 2020 Aug; 111(8):3045-3056. PubMed ID: 32473077
[TBL] [Abstract][Full Text] [Related]
16. Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas.
Bi XC; Liu JM; He HC; Ye YK; Han ZD; Dai QS; Liang YX; Cai C; Chen JH; Chen XB; Qin GQ; Zeng GH; Zhong WD
Clin Transl Oncol; 2012 Mar; 14(3):190-6. PubMed ID: 22374422
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of ADAM12-S: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis.
Taniguchi T; Asano Y; Akamata K; Aozasa N; Noda S; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
J Eur Acad Dermatol Venereol; 2013 Jun; 27(6):747-53. PubMed ID: 22540429
[TBL] [Abstract][Full Text] [Related]
18. A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma.
Mino N; Miyahara R; Nakayama E; Takahashi T; Takahashi A; Iwakiri S; Sonobe M; Okubo K; Hirata T; Sehara A; Date H
J Surg Oncol; 2009 Sep; 100(3):267-72. PubMed ID: 19544357
[TBL] [Abstract][Full Text] [Related]
19. EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma.
Tian L; Zhang Y; Chen Y; Cai M; Dong H; Xiong L
PLoS One; 2013; 8(3):e58069. PubMed ID: 23516431
[TBL] [Abstract][Full Text] [Related]
20. ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer.
Ma B; Ma Q; Jin C; Wang X; Zhang G; Zhang H; Seeger H; Mueck AO
Int J Clin Exp Pathol; 2015; 8(10):13279-83. PubMed ID: 26722530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
